|
1
|
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
|
N Engl J Med
|
2008
|
14.01
|
|
2
|
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2010
|
5.47
|
|
3
|
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
|
Lancet
|
2012
|
3.57
|
|
4
|
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
|
Atherosclerosis
|
2006
|
1.99
|
|
5
|
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.
|
Arterioscler Thromb Vasc Biol
|
2005
|
1.91
|
|
6
|
The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre study.
|
Ethn Dis
|
2004
|
1.73
|
|
7
|
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy.
|
Circulation
|
2011
|
1.51
|
|
8
|
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.
|
Circ Cardiovasc Genet
|
2015
|
1.50
|
|
9
|
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia.
|
J Pediatr
|
2009
|
1.49
|
|
10
|
Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.
|
J Infect Dis
|
2013
|
1.26
|
|
11
|
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
|
J Pediatr
|
2003
|
1.23
|
|
12
|
Familial hypercholesterolaemia: the Cape Town experience.
|
S Afr Med J
|
2008
|
1.08
|
|
13
|
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
|
Atherosclerosis
|
2007
|
1.02
|
|
14
|
Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia.
|
J Lipid Res
|
2003
|
0.91
|
|
15
|
The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans.
|
Circ Cardiovasc Genet
|
2012
|
0.89
|
|
16
|
Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape.
|
PLoS One
|
2013
|
0.89
|
|
17
|
Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease.
|
Cardiovasc J Afr
|
2012
|
0.88
|
|
18
|
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
|
J Am Coll Cardiol
|
2014
|
0.84
|
|
19
|
Renal tubular toxicity of HMG-CoA reductase inhibitors.
|
Nephrol Dial Transplant
|
2004
|
0.84
|
|
20
|
Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations.
|
Clin Chem
|
2005
|
0.83
|
|
21
|
Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies.
|
Circ Cardiovasc Imaging
|
2010
|
0.81
|
|
22
|
Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia.
|
Acta Paediatr
|
2006
|
0.81
|
|
23
|
Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond.
|
J Atheroscler Thromb
|
2016
|
0.78
|
|
24
|
Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype.
|
Clin Chim Acta
|
2006
|
0.77
|
|
25
|
The cardioprotective effect of wine on human blood chemistry.
|
Ann N Y Acad Sci
|
2002
|
0.76
|
|
26
|
The influence of glucocorticoids on lipid and lipoprotein metabolism and atherosclerosis.
|
S Afr Med J
|
2014
|
0.76
|
|
27
|
Severe hypertriglyceridemia in a patient with lupus.
|
Am J Med
|
2005
|
0.76
|
|
28
|
Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia.
|
J Clin Lipidol
|
2007
|
0.75
|
|
29
|
Alcohol--foe or friend?
|
S Afr Med J
|
2005
|
0.75
|
|
30
|
Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.
|
Curr Opin Endocrinol Diabetes Obes
|
2017
|
0.75
|
|
31
|
Dyslipidaemia in South Africa.
|
Cardiovasc J S Afr
|
2004
|
0.75
|
|
32
|
Pseudohyponatraemia in a patient with obstructive jaundice.
|
Clin Chim Acta
|
2005
|
0.75
|
|
33
|
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
|
Atherosclerosis
|
2003
|
0.75
|
|
34
|
Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia).
|
J Clin Lipidol
|
2008
|
0.75
|
|
35
|
Discovering familial hypercholesterolaemia.
|
S Afr Med J
|
2008
|
0.75
|